HeartSciences launches breakthrough ECG technology at Canadian Cardiovascular Congress

This article was originally published here

The MyoVista hsECG was developed using Continuous Wavelet Transform mathematics and goes beyond conventional ECG technology with new metrics to detect repolarization abnormalities. This new capability enables physicians to detect diastolic dysfunction which is typically diagnosed using tissue Doppler echocardiography.

The MyoVista hsECG, incorporates all of the capabilities of a full featured 12-lead resting ECG plus new proprietary informatics that assist in detecting diastolic dysfunction. Using machine learning, MyoVista hsECG technology detected diastolic dysfunction with 88 percent sensitivity, and 87 percent specificity, in a recent clinical trial at Mount Sinai Hospital in New York.*

“The MyoVista hsECG represents an exciting breakthrough in ECG technology,” said Mark Hilz, Chief Executive Officer, HeartSciences. “We look forward to introducing this breakthrough technology to the Canadian market.”

The device is also available across the European Union, where it received the CE (Conformité Européenne) Mark approval earlier this year. HeartSciences is also in the process of expanding distribution to Australia, the Middle East, Latin America and Asia-Pacific.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply